Beijing Wandong Medical Technology Co.,Ltd. (SHA:600055)
China · Delayed Price · Currency is CNY 13.11
0.00 (0.00%)
May 15, 2026, 9:44 AM CST
SHA:600055 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,248 | 1,215 | 1,428 | 1,161 | 1,067 | 1,102 |
Other Revenue | 131.93 | 131.93 | 96.27 | 75.73 | 54.23 | 54.15 |
| 1,380 | 1,347 | 1,524 | 1,237 | 1,121 | 1,156 | |
Revenue Growth (YoY) | -13.14% | -11.63% | 23.26% | 10.30% | -3.02% | 2.14% |
Cost of Revenue | 1,084 | 1,011 | 973.65 | 719.49 | 629.87 | 633.98 |
Gross Profit | 295.89 | 335.88 | 550.7 | 517.18 | 491.33 | 522.2 |
Selling, General & Admin | 396.72 | 404.71 | 286.52 | 299.22 | 241.1 | 255.23 |
Research & Development | 259.91 | 263.19 | 165.23 | 157.56 | 137.76 | 111.48 |
Other Operating Expenses | 26.31 | 13.29 | 14.83 | -24.93 | -18.02 | -25.88 |
Operating Expenses | 708.97 | 707.22 | 483.81 | 438.12 | 366.41 | 335.5 |
Operating Income | -413.08 | -371.35 | 66.89 | 79.06 | 124.93 | 186.69 |
Interest Expense | -1.27 | -1.27 | -1.65 | -1.25 | -1.47 | -1.51 |
Interest & Investment Income | 57.66 | 57.66 | 78.75 | 89.42 | 83.13 | 47.09 |
Currency Exchange Gain (Loss) | -12.27 | -12.27 | 4.72 | 0.57 | 10.02 | -1.9 |
Other Non Operating Income (Expenses) | -33.73 | -20.98 | -5.23 | -1.64 | -17.79 | -23.01 |
EBT Excluding Unusual Items | -402.12 | -348.22 | 143.49 | 166.16 | 198.82 | 207.36 |
Gain (Loss) on Sale of Investments | -1.52 | -0.87 | -3 | 34.59 | -3.47 | -2.14 |
Gain (Loss) on Sale of Assets | -0.03 | -0.08 | 0.12 | -0.67 | -1.92 | -0.25 |
Asset Writedown | -0.03 | -0.03 | -0.02 | - | -2.3 | - |
Legal Settlements | - | - | - | - | -0.18 | -0.06 |
Other Unusual Items | 48.69 | 48.69 | 26.27 | 13.25 | 1.49 | 2.31 |
Pretax Income | -355.02 | -300.51 | 166.86 | 213.33 | 192.44 | 207.22 |
Income Tax Expense | -76.71 | -72.72 | 8.22 | 22.52 | 20.4 | 26.96 |
Earnings From Continuing Operations | -278.32 | -227.79 | 158.64 | 190.81 | 172.04 | 180.26 |
Minority Interest in Earnings | -0.53 | -0.07 | -1.29 | -2.27 | 3.33 | 2.93 |
Net Income | -278.85 | -227.86 | 157.35 | 188.54 | 175.37 | 183.19 |
Net Income to Common | -278.85 | -227.86 | 157.35 | 188.54 | 175.37 | 183.19 |
Net Income Growth | - | - | -16.54% | 7.51% | -4.27% | -16.98% |
Shares Outstanding (Basic) | 701 | 703 | 702 | 701 | 659 | 536 |
Shares Outstanding (Diluted) | 701 | 703 | 702 | 701 | 659 | 536 |
Shares Change (YoY) | 0.06% | 0.12% | 0.22% | 6.31% | 23.08% | 0.01% |
EPS (Basic) | -0.40 | -0.32 | 0.22 | 0.27 | 0.27 | 0.34 |
EPS (Diluted) | -0.40 | -0.32 | 0.22 | 0.27 | 0.27 | 0.34 |
EPS Growth | - | - | -16.73% | 1.13% | -22.22% | -16.99% |
Free Cash Flow | -350.41 | -350.95 | 179.64 | 191.09 | 171.36 | 77.87 |
Free Cash Flow Per Share | -0.50 | -0.50 | 0.26 | 0.27 | 0.26 | 0.14 |
Dividend Per Share | - | - | 0.130 | 0.130 | 0.120 | 0.100 |
Dividend Growth | - | - | - | 8.33% | 20.00% | -23.08% |
Gross Margin | 21.44% | 24.93% | 36.13% | 41.82% | 43.82% | 45.17% |
Operating Margin | -29.93% | -27.57% | 4.39% | 6.39% | 11.14% | 16.15% |
Profit Margin | -20.20% | -16.92% | 10.32% | 15.25% | 15.64% | 15.85% |
Free Cash Flow Margin | -25.39% | -26.05% | 11.78% | 15.45% | 15.28% | 6.73% |
EBITDA | -372.89 | -332.28 | 101.5 | 112.13 | 156.21 | 221.21 |
EBITDA Margin | -27.02% | -24.67% | 6.66% | 9.07% | 13.93% | 19.13% |
D&A For EBITDA | 40.18 | 39.07 | 34.61 | 33.07 | 31.28 | 34.52 |
EBIT | -413.08 | -371.35 | 66.89 | 79.06 | 124.93 | 186.69 |
EBIT Margin | -29.93% | -27.57% | 4.39% | 6.39% | 11.14% | 16.15% |
Effective Tax Rate | - | - | 4.92% | 10.56% | 10.60% | 13.01% |
Revenue as Reported | 1,347 | 1,347 | 1,524 | 1,237 | 1,121 | 1,156 |
Advertising Expenses | - | 2.21 | 3.6 | 2.41 | 2.85 | 2.82 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.